FDA Approves CAPVAXIVE, Sixth Product Using Pfenex Expression Technology; Ligand Pharmaceuticals Entitled To Royalties On Global Sales
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved CAPVAXIVE, the sixth product utilizing Pfenex Expression Technology. Ligand Pharmaceuticals (LGND) is entitled to royalties on global sales.
June 18, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ligand Pharmaceuticals will receive royalties from the global sales of CAPVAXIVE, which has just been approved by the FDA.
The FDA approval of CAPVAXIVE, which uses Pfenex Expression Technology, directly benefits Ligand Pharmaceuticals as they are entitled to royalties from its global sales. This is likely to positively impact LGND's revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100